OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Go back to OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer| VERACYTE (NASDAQ: VCYT) | Delayed: 53.63 +2.34 (4.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.29 | 52 Week High | $8.45 | |||
| Open | $51.96 | 52 Week Low | $4.21 | |||
| Day High | $53.81 | P/E | N/A | |||
| Day Low | $51.92 | EPS | $-1.52 | |||
| Volume | 4,155,449 | |||||
